Solutions for Treg immunomodulation in the TME
Relying on the technology platform of the tumor microenvironment center, Alfa Oncology provides global collaborators with solutions and related services to study the relationship between tumor immunity and regulatory T cells (Treg) in the tumor microenvironment (TME), helping them to rapidly achieve their research goals.
Regulatory T cells (Treg) are a subset of T cells with immunomodulatory functions that have been identified in recent years and play an important regulatory homeostatic role in the induction and maintenance of immune tolerance to self-substances, maintaining the body's immune self-stability and regulating the immune response. Their deficiency / functional defects are closely related to the development and progression of autoimmune and inflammatory diseases and the stability of the body's internal environment. The presence of a large number of Treg cells in the tumor microenvironment (TME) is believed to be the "culprit" that helps tumor cells to evade the body's immune surveillance. In the anti-tumor immune response, Treg cells negatively regulate the body's immune action against tumor cells, exerting a suppressive effect, and their increase can suppress the anti-tumor immune effect and promote tumor growth.
Treg can inhibit the function of immune effector cells through various mechanisms, including: Treg interferes with the metabolic function of effector cells, Treg secretes suppressive cytokines to inhibit the function of effector cells, Treg secretes granzyme and perforin to kill effector cells, etc. Because of the importance of Treg in the regulation of immunity, it provides new thinking for tumor immunotherapy and has good clinical application prospects.
Regulatory T cells in the tumor microenvironment (TME) are involved in tumor immune regulation through various mechanisms. In-depth study of the relationship between regulatory T cells and tumor immunity can help further reveal the mechanism of tumorigenesis, development and migration. Meanwhile, it is also the current hot spot of tumor immunity research, which may provide new ideas for future tumor prevention and treatment, and lay a more solid theoretical basis to truly realize tumor precision medicine and better improve the long-term prognosis of patients. Alfa Oncology has established a tumor microenvironment technology platform and developed several emerging technologies through which it helps global collaborators to deeply explore the relationship between tumor immunity and regulatory T cells (Treg) in the tumor microenvironment (TME), hoping to find potential targets for tumor therapy in the process and provide new ideas for clinical anti-tumor treatment.
Flow cytometry: phenotype, cytokines. Surface staining using anti-CD4-FITC antibody, anti-CD25-PE antibody and anti-CD127-APC antibody to sort high purity Treg by detecting cell surface markers CD4, CD25 and CD127.
Treg cell isolation and purification (immunomagnetic beads and flow sorting)
In vivo and in vitro induction of differentiation assays
In vitro and in vivo neutralization assays (functional purification grade antibodies)
ELISA and ELISPOT. ELISPOT (enzyme-linked immunospot assay) is a solid-phase enzyme-linked immunospot technique for in vitro detection of specific antibody-secreting cells and cytokine-secreting cells, and is a novel technique developed by combining ELISA technology and cell culture technology. It can be used for the study of Treg and tumor immunomodulation.
Alfa Oncology is committed to supporting scientists in making breakthrough scientific discoveries and developing new applications to accelerate new drug discovery and scientific diagnosis and treatment. Our high-performance scientific instruments and high-value solutions enable scientists to explore the mysteries of life at the tumor microenvironment level. Please tell us your project requirements, and we will provide you with a full service from solution to report. If you have any questions, please feel free to contact us.